Approximately 50% of patients participating in that trial were subsequently rerandomized to receive 3 years of extended anastrozole versus no further treatment (ABCSG-6a ref. 537 women included in this study had been randomized into the prospectively randomized adjuvant endocrine trial ABCSG-6 between 19, and had received 5 years of adjuvant tamoxifen ( 12). This study is part of the ABCSG translational research program (abcsg.research). These results may guide therapeutic strategies in patients with ER +/HER2 − early breast cancer and contribute to our understanding of appropriate patient selection. We found that focal ESR1 amplification is an independent and powerful predictor for long-term distant recurrence-free and breast cancer–specific survival in postmenopausal women with endocrine-responsive early-stage breast cancer who receive adjuvant endocrine therapy. By using tumor tissues from tamoxifen-treated postmenopausal women with endocrine-responsive, early breast cancer, who were randomized into the prospective ABCSG-06 phase III study, we have investigated the value of ESR1 amplification in predicting the long-term clinical outcome.

Within the subgroup of ER + tumors, however, no receptor-associated biomarker exists which identifies patients with a particularly good long-term outcome. Estrogen receptor (ER) expression is a favorable prognostic parameter in breast cancer, and a predictor for response to endocrine therapy.

Submitting to the alpha free download